Synthesis, antidotal effects and HPLC behavior of some novel pyridinium aldoximes

Current Organic Chemistry

Volumn 14, Issue 5, 2010, Pages 447-456

  Laufer, R ^a   Kalasz H ^a   Musilek, K ^b   Szegi, P ^a   Darvas, F ^c   Kuca, K ^b   Tekes, K ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c NONE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORUS COMPOUNDS;

ACETYLCHOLINESTERASE ENZYMES; ACTIVE SITE; ALDOXIMES; BASIC CHARACTERISTICS; ORGANOPHOSPHORUS COMPOUNDS; PYRIDINIUM; REACTIVATION PROCESS;

AMINO ACIDS;

EID: 77951254997     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527210790601206     Document Type: Article

References (58)

1. th ed., 2008, pp: 883-930.
2. Eyer, P. The role of oximes in the management of organophosphorous pesticide poisoning. Toxicol. Rev., 2003, 22, 165-190.
3. Gupta, R.C. Handbook of Toxicology of Chemical Warfare Agents. Elsevier: London, 2009, p. 147.
4. rd ed., 2004, pp. 1475-1496.
5. Wilson, I.B.; Ginsburg, S. A powerful reactivator of alkylphosphate inhibited acetylcholinesterase. Biochim. Biophys. Acta, 1955, 28, 168-170.
6. Thompson, D.F.; Thompson, G.D.; Greenwood, R.B.; Trammel, H.L.: Therapeutic dosing of pralidoxime chloride. Drug Intell. Clin. Pharm., 1987, 21, 590-3.
7. Petroianu, G.A.; Arafat, K.; Kuca, K.; Kassa, J.: Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acetylcholinesterase inhibited by paraoxon. J. Appl. Toxicol., 2006, 26, 64-71.
8. Erdmann, W.D.; Engelhard, H. Pharmakologisch-toxikologische Unter-suchungen mit dem Dichloride des Bis-(4-hydroxyimminomethyl-pyridinium-(1)-methyl-äthers, einem neuen Esterase-Reaktivator. Arzneimittelforschung, 1964, 14, 5-11.
9. Thiermann, H.; Mast, U.; Klimmek, R.; Eyer, P.; Hibler, A.; Pfab R.; Felgenhauer, N.; Zilker, T. Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients. Hum. Exp. Toxicol., 1997, 16, 473-80.
10. Poziomek, E.J.; Hackley Jr., B.E.; Steinberg, G.M. Pyridinium aldoximes. J. Org. Chem., 1958, 23, 714-7.
11. Cassel, G.; Kalsson, L.; Waara, L.; Ang, K.W.; Göransson-Nyberg, A. Pharmacokinetics and effects of HI-6 in blood and brain of soman-intoxicated rats: A microdialysis study. Eur. J. Pharmacol., 1997, 332, 43-52.
12. Krummer, H.; Thiermann, H.; Worek, F.; Eyer, P. Equipotent cholinesterase reactivation in vitro by the nerve agent antidotes HI-6 dichloride and HI-6 dimethanesulphonate. Arch. Toxicol., 2002, 76, 589-95.
13. Antonijevic, B.; Stojiljkovic, M. P. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res., 2007, 5, 71-82.
14. Musilek, K.; Kuca, K.; Jun, D.; Dolezal, M. Progress in synthesis of new acetylcholinesterase reactivators in period 1990-2004. Curr. Org. Chem., 2007, 11, 229-38.
15. Kuca, K.; Jun, D.; Musilek, K. Structural requirements of acetylcholinesterase reactivators. Mini Rev. Med. Chem., 2006, 6, 269-77.
16. Kuca, K.; Cabal, J.; Musilek, K.; Jun, D.; Bajgar, J. Effective bisquaternary reactivators of tabun-inhibited AChE. J. Appl. Toxicol., 2005, 25, 491-5.
17. Musilek, K.; Jun, D.; Cabal, J.; Kassa, J.; Gunn-Moore, F.; Kuca, K. Design of a potent reactivator of tabun-inhibited acetylcholinesterase - synthesis and evaluation of (E)-1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethyl-pyridinium)-but-2-ene dibromide (K203). J. Med. Chem., 2007, 50, 5514-8.
18. Musilek, K.; Holas, O.; Kuca, K.; Jun, D.; Dohnal, V.; Opletalova, V.; Dolezal, M. Novel series of bispyridinium compounds bearing a (Z)-but-2-ene Linker - Synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett., 2007, 17, 3172-6.
19. Musilek, K.; Holas, O.; Kuca, K.; Jun, D.; Dohnal, V.; Oplet-aletal/et-alova, V.; Dolezal, M. Synthesis of monooxime-monocarbamoyl bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. J. Enzym. Inhib. Med. Chem., 2008, 23, 70-6.
20. Kassa, J.; Karasova, J.; Musilek, K.; Kuca, K. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology, 2008, 243, 311-6.
21. Kovarik, Z.; Lucic Vrdoljak, A.; Berend, S.; Catalinic, M.; Kuca, K.; Musilek, K.; Radic, B. Evaluation of oxime K203 as antidote in tabun poisoning. Arh. Hig. Rada Toksikol., 2009, 60, 19-26.
22. Musilek, K.; Holas, O.; Jun, D.; Dohnal, V.; Gunn-Moore, F.; Opletalova, V.; Dolezal, M.; Kuca, K. Monooxime reactivators of acetylcholinesterase with (E)-but-2-ene linker - Preparation and reactivation of tabun and paraoxon-inhibited acetylcholinesterase. Bioorg. Med. Chem., 2007, 15, 6733-41.
23. Musilek, K.; Kuca, K.; Jun, D.; Dohnal, V.; Dolezal, M. Synthesis of a novel series of bispyridinium compounds bearing a xylene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase. J. Enzym. Inhib. Med. Chem., 2005, 20, 409-15.
24. Musilek, K.; Holas, O.; Kuca, K.; Jun, D.; Dohnal, V.; Dolezal, M. Synthesis of the novel series of non-symmetrical bispyridinium compounds bearing xylene linker and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. J. Enzym. Inhib. Med. Chem., 2007, 22, 425-32.
25. Musilek, K.; Kucera, J.; Jun, D.; Dohnal, V.; Opletalova, V.; Kuca, K. Monoquaternary pyridinium salts with modified side chain - synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase. Bioorg. Med. Chem., 2008, 16, 8218-23.
26. Musilek, K.; Holas, O.; Kuca, K.; Jun, D.; Dohnal, V.; Dolezal, M. Synthesis of asymmetrical bispyridinium compounds bearing cyano-moiety and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett., 2006, 16, 5673-6.
27. Musilek, K.; Kuca, K.; Jun, D.; Dolezal, M. Synthesis of bispyridinium compounds bearing propane linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. Lett. Org. Chem., 2006, 3, 831-5.
28. Bokonjic, D.; Stojiljkovic, M.P.; Stulic, D.; Kovacevic, V.; Maksimovic, M. Application of response surface modeling for evaluation of the efficacy of a HI/6/trimedoxime mixture against tabun and soman poisoning in rats. Arch. Toxicol. Kinet. Xenobiot. Metab., 1993, 1, 223-32.
29. Kuca, K.; Bielavsky, J.; Cabal, J.; Kassa, J. Synthesis of a new reactivator of tabun-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett., 2003, 13, 3545-7.
30. Maxwell, D.M.; Koplovitz, I.; Worek, F.; Sweeney, R.E. A structure-activity analysis of the variation in oxime efficacy against nerve agents. Toxicol. Appl. Pharmacol., 2008, 231, 157-64.
31. Petroianu, G. A.; Arafat, K.; Kuca, K.; Kassa, J. Five oximes (K-27, K-33, K-48, Bl-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acetyl cholinesterase inhibitied by paraoxon. J. Appl. Toxicol., 2006, 26, 64-71.
32. Petroianu, G. A.; Nurulain, S. M.; Nagelkerke, N.; Al-Sultan, M. A. H.; Kuca, K.; Kassa, J. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon. J. Appl. Toxicol., 2006, 26, 262-8.
33. Kuca, K.; Kassa, J. A comparison of the ability of a new bispyridinium oxime-1-(4-hydroxyiminomethylpyridinium)-4-(4-carbamoyl-pyridinium) butane dibromide and currently used oximes to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods. J. Enzyme Inhib. Med. Chem., 2003, 18, 529-35.
34. Kassa, J.; Jun, D.; Kuca, K. A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in cyclosarin-and tabun-poisoned rats. J. Enzyme Inhib. Med. Chem., 2007, 22, 297-300.
35. Kalász, H.; Hasan, M.Y.; Sheen, R.; Kuca, K.; Petroianu, G.; Ludányi, K.; Gergely, A.; Tekes, K. HPLC analysis of K-48 concentration in plasma. Anal. Bioanal. Chem., 2006, 385, 1062-7.
36. Tekes, K.; Hasan, M.Y.; Sheen, R.; Kuca, K.; Petroianu, G.; Ludányi, K.; Kalász, H. HPLC determination of the serum concentration of K-27, a novel oxime-type cholinesterase reactivator. J. Chromatogr. A., 2006, 1122, 84-7.
37. Gyenge, M.; Kalász, H.; Petroianu, G.A.; Laufer, R.; Kuca, K. Tekes, K. Measurement of K-27, an oxime-type cholinesterase reactivator by high-performance liquid chromatography with electrochemical detection from different biological samples. J. Chromatogr., 2007, 1161, 146-51.
38. Csermely, T.; Kalász, H.; Petroianu, G.; Kuca, K.; Darvas, F.; Ludanyi, K.; Mudhafar, A.A.; Tekes, K. Analysis of Pyridinium Aldoximes - A Chromatographic Approach. Curr. Med. Chem., 2008, 15, 2401-18.
39. Kalász, H.; Laufer, R.; Szegi, P.; Kuca, K.; Musilek, K.; Tekes, K. HPLC study of the pharmacokinetics of K-203. Acta Chromatogr., 2008, 20, 575-84.
40. Kalász, H.; Fürész, J.; Tekes, K. Monitoring the pharmacokinetics of pyridinium aldoximes in the body. Mini Rev. Med. Chem., 2009, 9, 448-62.
41. The PrologP program is a Trademark of CompuDrug Inc., www.compudrug.com
42. Molnár, L.; Keser, G.M.; Papp, A.; Gulyás, Zs.; Darvas, F. A neural network based prediction of octanol/water partition coefficients using atomic5 fragmental descriptors. Bioorg. Med. Chem. Lett., 2004, 14, 851-3.
43. Kuca, K.; Cabal, J.; Jun, D; Musilek, K. In vitro reactivation potency of acetylcholinesterase reactivators - K074 and K075 - to reactivate tabun-inhibited human brain cholinesterases. Neurotox. Res., 2007, 11, 101-106.
44. Kassa, J.; Jun, D.; Kuca, K. The reactivating and therapeutic efficacy of oximes to counteract Russian VX poisonings. Int. J. Toxicol., 2006, 25, 397-401.
45. Kassa, J. The influence of oxime and anticholinergic drug selection on the potency of antidotal treatment to counteract acute toxic effects of tabun in mice. Neurotox. Res., 2006, 9, 59-62.
46. Kassa, J.; Humlicek, V. A comparison of the potency of newly developed oximes (K074, K075) and currently available oximes (obidoxime, trimedoxime, HI-6) to counteract acute toxic effects of tabun and cyclosarin in mice. Drug Chem. Toxicol., 2008, 31, 127-35.
47. Kassa, J.; Karasova, J.; Musilek, K.; Kuca, K. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology, 2008, 243, 311-6.
48. Horváth, Cs.; Melander, W.; Molnár, I.; Molnár, P. Enhancement of retention by ion-pair formation in liquid chromatography with nonpolar stationary phases. Anal. Chem., 1977, 49, 2295-305.
49. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sumof fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem., 2000, 43, 3714-7.
50. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar molar surface properties predict the intestinal absorption of drugs in humans. Pharm. Res., 1997, 14, 568-71.
51. Stenberg, P.; Luthman, K.; Ellens, H.; Pin Li, Ch.; Smith, P.L.; Lago, A.; Elliot, J.D.; Artursson, P. Prediction of intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharm. Res., 1999, 16, 1520-6.
52. Clark, D.E. Rapid calculation of polar molecular surface area and its application to he prediction of transport phenomena. 2. Prediction of blood-brain-barrier penetration. J. Pharm. Sci., 1999, 88, 815-21.
53. Kelder, J.; Grootenhuis, P.D.J.; Bayada, D.M.; Delbressine, L.P.C.; Ploemen, J.-P. Polar molecularsurface area as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res., 1999, 16, 1514-9.
54. Sakurada, K.; Matsubara, K.; Shimizu, K.; Shiono, H.; Seto, Y.; Tsuge, K.; Yoshino, M.; Sakai, I.; Mukoyama, H.; Takatori, T.: Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem. Res., 2003, 28, 1401-7.
55. Kalász, H.; Szök, É.; Tábi, T.; Petroianu, G.A.; Lorke, D.E.; Alafifi, O.A.; Almerri, S.A.; Tekes, K. Analysis of pralidoxime in serum, brain and CSF of rats. Med. Chem., 2009, 5, 237-41.
56. Kalász, H.; Tekes, K. Terrorist attacks or poisoning by organophosphate pesticides - Is there any defence? BenSci., 2009, 1, 3-6.
57. Okuno, S.; Sakurada, K.; Ohta, H.; Ikegaya, H.; Kazui, Y.; Akutso, T.; Takatori, T.; Iwadate, K.: Blood-brain barrier penetration of novel pyridine aldoxime methiodide (PAM)-type oximes examined by brain microdialysis with LC-MS/MS. Toxic. Appl. Pharmacol., 2008, 227, 8-15.
58. Geldenhuys, W.J.; Lockman, P.R.; McAfee, J.H.; Fitypatrick, K.T.; Van der Schzf, C.J.; Allen, D.D.: Molecular modeling studies on the active binding site of blood/brain barrier choline transporter. Bioorg. Med. Chem., 2004, 14, 3085-92.